Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 HKD | +0.71% | +11.02% | -3.42% |
03/04 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
03/04 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Bearish | Bearish | Bearish |
Resistance | 1.400 | 1.550 | 1.700 |
Spread/Res. | +0.71% | -9.03% | -17.06% |
Spread/Supp. | +11.02% | +11.02% | +10.16% |
Support | 1.270 | 1.270 | 1.280 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- 1672 Stock
- Charts Ascletis Pharma Inc.